Genetically engineered bacterium and application of genetically engineered bacterium in high-yield ibrevicin

By knocking out the two-component regulator LiaRS for Bacillus, a genetically engineered strain with high yield of ipatin was constructed, which solved the problem of low yield of wild-type strains, and achieved significant improvement of ipatin yield and antibacterial activity. enhancement.

CN119081983AInactive Publication Date: 2024-12-06CHINA NATIONAL TOBACCO CORPORATION HUNAN PROVINCIAL CORPORATION
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411435311.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The low yield of ipatin in wild-type Bacillus bacillus X23 limits its effectiveness in biological control and antibiotic applications.

Method used

By conducting directed genetic modification of Bacillus sausage, knocking out the two-component regulator LiaRS, and constructing a homologous recombinant knockout vector, a genetically engineered strain capable of high yielding ipatin was successfully constructed.

Benefits of technology

The yield of ichinin increased by 1.3 times after fermentation of genetically engineered strains, significantly enhancing the inhibitory ability of Cyperus and laying the foundation for its development in microbial-derived pesticides and medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119081983A_ABST
    Figure CN119081983A_ABST
Patent Text Reader

Abstract

The invention discloses a genetically engineered bacterium and application of the genetically engineered bacterium in high-yield ibrevicin, and belongs to the technical field of genetic engineering and microorganisms. According to the genetically engineered bacterium disclosed by the invention, wild brevibacillus brevis X23 is taken as a starting strain, a two-component regulatory factor LiaRS knockout vector is constructed, and the two-component regulatory factor LiaRS in the wild brevibacillus brevis X23 (X23-WT) is knocked out by utilizing a homologous recombination technology, so that the corresponding engineered bacterium delta liaR / S for high yield of ibrevimycin is obtained. The genetically engineered bacterium subjected to directional genetic modification can improve the yield of the ibrevicin, the culture mode is convenient and fast, the yield is high, and a solid foundation is laid for development and utilization of the ibrevicin in microbial source pesticides and medicines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of genetic engineering and microbial technology, and more specifically to a genetic engineering bacterium and its application in high-yield edemacin. Background Art

[0002] Bacillus is a multifunctional biocontrol bacterium with a wide range of applications in industry, agriculture and medicine, especially in the biological control of plant diseases and insect pests and enhancing the stress resistance of crops.

[0003] Edeines are composed of four non-protein amino acid residues (β-Tyr / β-Phe, Isoserine, DAPA and DAHAA), a glycine and a polyamine, and contain four components (i.e., edeine A, B, D and F). Each component has two isomers, α (A) and β (B). The difference lies in whether the carboxyl group in β-isoserine (Isoserine) forms a peptide bond with the α-amino group or the β-amino group in 2,3-diaminopropionic acid (DAPA). Edeines have strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, mycoplasmas and fungi, and also have immunosuppressive activity. Its mode of action is closely related to concentration. When the concentration is less than 15μg / mL, it can inhibit DNA synthesis, and when the concentration exceeds 150μg / mL, it becomes a broad-spectrum inhibitor (DNA synthesis, protein translation and synthesis). Therefore, edeines have good potential for development as agricultural or medical antibiotics.

[0004] Wild-type Bacillus brevis X23 is a broad-spectrum antagonistic bacterium isolated from tobacco rhizosphere soil, but the production of edeines in the wild-type X23 strain is low, which limits its biocontrol effect and application as an agricultural antibiotic.

[0005] Therefore, providing a genetically engineered bacterium and its application in high-yield edemacin is an urgent problem to be solved by those skilled in the art. Summary of the invention

[0006] In view of this, the present invention provides a genetically engineered bacterium and its application in high-yield edemectin. The genetically engineered bacterium can effectively increase the yield of edemectin by performing directed genetic modification on Bacillus brevis.

[0007] In order to achieve the above object, the present invention adopts the following technical solution:

[0008] A genetically engineered bacterium, using Brevibacillus brevis X23 as the original strain, and knocking out the two-component regulator LiaRS;

[0009] The gene numbers of the two-component regulator LiaRS are A616_RS05710 (sensor histidine kinase) and A616_RS05715 (response regulator transcription factor), and the nucleotide sequences are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively.

[0010] Further, a method for constructing a genetically engineered bacterium comprises the following specific steps:

[0011] (1) Using the upstream and downstream homology arms of LiaRS, resistance genes and vector backbone, a homologous recombination knockout vector was constructed;

[0012] The nucleotide sequence of the resistance gene is shown in SEQ ID NO.3; the resistance gene is Apra R ;

[0013] The upstream homology arm nucleotide sequence of the LiaRS is shown in SEQ ID NO.12; the downstream homology arm nucleotide sequence is shown in SEQ ID NO.13;

[0014] The vector backbone is obtained by amplification using pE194 plasmid as template and primers pE194-F / pE194-R;

[0015] (2) The LiaRS in the genome of Bacillus brevis X23 was knocked out by homologous recombination technology to obtain a genetically engineered bacterium.

[0016] Further, the sequences of primers pE194-F / pE194-R are as follows:

[0017] pE194-F: cagctgcctcgcgcgtttcggtga; SEQ ID NO.6;

[0018] pE194-R: gttaagggatgcataaactgcatc; SEQ ID NO. 7.

[0019] Furthermore, the genetically engineered bacteria are used in high-yield ivermectin.

[0020] Furthermore, the genetically engineered bacteria are used to inhibit Ralstonia solanacearum.

[0021] Furthermore, the genetically engineered bacteria constructed by the method described above are used in high-yield ivesinopril.

[0022] Further, the application of the genetically engineered bacteria constructed by the method described above in inhibiting Ralstonia solanacearum

[0023] It can be seen from the above technical scheme that compared with the prior art, the present invention discloses a genetically engineered bacterium and its application in high-yield edemycin. The present invention constructs a homologous recombination knockout vector, and knocks out the two-component regulatory factors LiaRS (gene number: A616_RS05710 and A616_RS05715) in the genome of wild-type Bacillus brevis in combination, thereby successfully constructing an engineered bacterium capable of high-yield edemycin; the Bacillus brevis engineered bacterium ΔliaR / S constructed by the present invention has an edemycin yield that is 1.3 times higher than that of the wild-type Bacillus brevis X23 after fermentation; the engineered bacteria have laid a solid foundation for the development and utilization of edemycin in microbial pesticides and medicines. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0025] Figure 1 The accompanying drawing is a flow chart of the present invention for constructing a genetically engineered strain using a knockout vector;

[0026] Among them, A is the knockout vector constructed by Red / ET homologous recombination technology (four linear fragments are recombined into a circular knockout plasmid), LLHR is the abbreviation of line-line recombination; B is a schematic diagram of in vivo homologous recombination knockout of LiaRS (the upstream and downstream homologous arms of LiaRS contained in the knockout vector undergo double exchange with the corresponding genomic positions), Apra R The LiaRS was replaced to obtain the genetically engineered bacteria ΔliaRS;

[0027] Figure 2 The accompanying drawing is a colony PCR double primer identification diagram of the engineered bacteria of Bacillus brevis obtained by the present invention;

[0028] Among them, A is a schematic diagram for identifying transformants after the knockout vector was transferred into the wild-type X23, and CK is a negative control; B is a schematic diagram for double primer identification after double exchange; M: DL5000 Marker; Lanes 1-3 are three transformants;

[0029] Figure 3 The accompanying drawings are growth curves of the engineered bacillus brevis ΔliaR / S of the present invention and the wild-type bacillus brevis X23-WT;

[0030] Figure 4 The accompanying drawings show the dynamic changes of the relative expression of edeP in the engineered bacterium ΔliaR / S of Brevibacillus sp. of the present invention;

[0031] Figure 5 The accompanying drawing is a graph showing the inhibition of the bacterial wilt pathogen by the fermentation liquid of the engineered bacillus brevis ΔliaR / S obtained in the present invention;

[0032] Among them, A: the inhibitory ability of the fermentation supernatants of X23-WT and ΔliaR / S against Ralstonia solanacearum at 12, 24, 36, 48, 60 and 72 h;

[0033] B: Statistics and significance analysis of the inhibition zone radius of X23-WT and ΔliaR / S;

[0034] Note: ***, P<0.001, **, P<0.01;

[0035] Figure 6 The attached figure is a HPLC-MS detection diagram of edemacin produced by the engineered Bacillus brevis strain ΔliaR / S and X23-WT obtained in the present invention;

[0036] A: The yields of edemacin of wild-type X23 and engineered strains were compared; HPLC-MS analysis showed that the retention time of edemacin was 0.3 min (indicated by the red dotted line);

[0037] B: Mass spectra of edemacin A and edemacin B, molecular ions of edemacin A and edemacin B [M+H] + They are 755.4417 and 797.4631 respectively;

[0038] C: Changes in the production of edemacin between wild-type X23 and genetically engineered strains; data are presented as the average of three independent experiments; error bars represent standard deviation (SD); percentages represent fold increase. DETAILED DESCRIPTION

[0039] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0040] The sources of the biological materials used in the examples are as follows: wild-type Bacillus brevis X23 (see patent 201910834175.5): provided by the College of Plant Protection, Hunan Agricultural University; vector pE194 (see patent 201910834175.5), i.e., pBR322-ErmB-194ori, preserved by the Hunan Institute of Microbiology; resistance gene Apra R :Contains the apramycin resistance gene Apra RThe plasmid pSET152 was deposited by Hunan Institute of Microbiology.

[0041] Restriction endonucleases BstZ17I and SmaI were purchased from NEB.

[0042] Example 1

[0043] The two-component regulator LiaRS (gene number: A616_RS05710 and A616_RS05715) in the genome of wild-type Bacillus brevis X23 was knocked out using Red / ET homologous recombination technology.

[0044] The nucleotide sequence of A616_RS05710 is shown in SEQ ID NO.1.

[0045] atgcgtcgacagcgattggcaagtattcagtggcaatacgtgcgctatggcatgttactggccgtcagtgcaattactgccgcgtttatttgtttcttttggctatactttttatggagagatcaccccgggattcatcggtggtacaacgaaatgattagcgaccgcaacttcatgtggtggcttcaagaatatataggcatcaatctgcctgccgatccagagggcttgattcagcttgctgcttttgttgtctctttgcctgcaggtgtcttagtggcattgatcatttcctatatcattggcaatttgttgaaaaagagactcagtgtattgtgggaagctgccatgaagcttgggcgcgggatgctgtcgtatcgggttccagaattgggcgtcgatgaagtcggcgaattaggatggcagatcaatcgcttggcttcacaatgggaagagcaagtggcatctttgcagcggctgtcgaaccacaatgcggctctcgcagaacaattgaagcatgcagcggtaacagaggagcgacagagattggcgagagaactgcatgatgcagtcagtcagcagctgttcgccatcgcgatgacgactgcggcgatgaaacggcttgtagaaaaaaatccgcaacgtgcagcacaacagattgaattggtcgaagagatggcagcagcagcacaagcggagatgagggcattgctcttgcatcttcgcccggctacgttacaaaacaagtcattgaaggaagccattctggaacttttagatgagctgacgcgtaaaaataccatgcagctttcttgggagatcgaagacgtcgaaggcttgccgagtggaattgaggatcatttgttccgtattttgcaggagtccttgtccaatacattgcggcatgccagagctacccagattacagtgaagctgtttacgctgcaagagcaggtccgcctgcgagtaacggatgacggtgttggttttgatccggatggggagaaaatgacgtcctacggtttgcgcagcatgcaagagcgcgtagcagaggtcggaggctccatggagatttactcggcaattgggaaggggacgcaaattgaggtccgtattcctctaatgtcacagacggaacgggaagggtga; SEQ ID NO.1.

[0046] The nucleotide sequence of A616_RS05715 is shown in SEQ ID NO.2.

[0047] ; SEQ ID NO.2.

[0048] Wild-type Brevibacillus brevis X23 was used as the original strain to construct a homologous recombination knockout vector, and LiaRS was knocked out to achieve efficient expression of ivermectin.

[0049] (1) PCR amplification of the screening marker Apra R (Apramycin resistance) and vector backbone

[0050] Plasmid pSET152 was used as template and primers Apra-F1 / Apra-R1 were used to amplify the resistance gene fragment (Apra R , containing the resistance gene Apra R The promoter sequence of resistance gene Apra R The nucleotide sequence is shown in SEQ ID NO.3.

[0051] Resistance gene Apra R The nucleotide sequence:

[0052] gatctgcaatttgaataataaccactcctttgtttatccaccgaactaagttggtgttttttgaagcttgaattagatatttaaaagtatcatatctaatattataactaaattttctaaaaaaaacattgaaataaacatttattttgtatatgatgagataaagttagtttattggataaacaaactaactcaattaagatagttgatggataaacttgttcacttaaatcaaaggaggcatatcaaatgcaatacgaatggcgaaaagccgagctcatcggtcagcttctcaaccttggggttacccccggcggtgtgctgctggtccacagctccttccgtagcgtccggcccctcgaagatgggccacttggactgatcgaggccctgcgtgctgcgctgggtccgggagggacgctcgtcatgccctcgtggtcaggtctggacgacgagccgttcgatcctgccacgtcgcccgttacaccggaccttggagttgtctctgacacattctggcgcctgccaaatgtaaagcgcagcgcccatccatttgcctttgcggcagcggggccacaggcagagcagatcatctctgatccattgcccctgccacctcactcgcctgcaagcccggtcgcccgtgtccatgaactcgatgggcaggtacttctcctcggcgtgggacacgatgccaacacgacgctgcatcttgccgagttgatggcaaaggttccctatggggtgccgagacactgcaccattcttcaggatggcaagttggtacgcgtcgattatctcgagaatgaccactgctgtgagcgctttgccttggcggacaggtggctcaaggagaagagccttcagaaggaaggtccagtcggtcatgcctttgctcggttgatccgctcccgcgacattgtggcgacagccctgggtcaactgggccgagatccgttgatcttcctgcatccgccagaggcgggatgcgaagaatgcgatgccgctcgccagtcgattggctga; SEQ ID NO.3.

[0053] Using the pE194 plasmid as a template, the vector backbone (pE194) was amplified with primers pE194-F / pE194-R.

[0054] The primer sequences are as follows:

[0055] Apra-F1: taccgttcgtatagcatacattatacgaagttatgatctgcaatttgaataataacc; SEQ ID NO.4;

[0056] Apra-R1: taccgttcgtataatgtatgctatacgaagttattcagccaatcgactggcgagcg; SEQ ID NO.5;

[0057] pE194-F: cagctgcctcgcgcgtttcggtga; SEQ ID NO.6;

[0058] pE194-R: gttaagggatgcataaactgcatc; SEQ ID NO.7.

[0059] PCR reaction system (taking 10 μL system as an example): 2×PrimerSTAR Max (Takara) 5 μL, upstream primer (10 μM) 0.3 μL, downstream primer (10 μM) 0.3 μL, template (concentration of about 20 ng / μL) 0.3 μL, sterile double distilled water (ddH2O) 4.1 μL.

[0060] The reaction conditions were as follows: pre-denaturation at 94°C for 5 min; denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s, for 35 cycles; and extension at 72°C for 10 min.

[0061] (2) PCR amplification of the homology arms at both ends of LiaRS:

[0062] Using the total DNA of Bacillus brevis X23 strain as a template, primers LiaRS-F1 and LiaRS-R1 were designed to amplify the upstream homology arm of about 1 kb; LiaRS-F2 and LiaRS-R2 were designed to amplify the downstream homology arm of about 1 kb. The primer sequences are as follows:

[0063] LiaRS-F1:

[0064] ataggcacacgaaaaacaagttaagggatgcagtttatgcatcccttaaccattccgcctgcattcatc; SEQ ID NO.8;

[0065] LiaRS-R1:

[0066] tcaaattgcagatcataacttcgtataatgtatgctatacgaacggtacttgccaatcgctgtcgacgc;SEQ ID NO.9;

[0067] LiaRS-F2:

[0068] agtcgattggctgaataacttcgtatagcatacattatacgaacggtaatttacgtgcatacgcgtagc;SEQ ID NO.10;

[0069] LiaRS-R2:

[0070] atgtgtcagaggttttcaccgtcatcaccgaaacgcgcgaggcagctgctcagcggcgtatccgttaag; SEQ ID NO. 11.

[0071] PCR reaction system: same as above.

[0072] The reaction conditions were: 94°C pre-denaturation for 5 min; 94°C denaturation for 30 s, 55°C annealing for 30 s, 72°C extension for 30 s, 35 cycles; 72°C extension for 10 min. The upstream homologous sequence fragment HAF (as shown in SEQ ID NO.12) and the downstream homologous sequence fragment HAR (as shown in SEQ ID NO.13) were recovered using a PCR recovery kit.

[0073] Upstream homologous sequence fragment nucleotide sequence:

[0074]

[0075] Nucleotide sequence of downstream homologous sequence fragment:

[0076] atttacgtgcatacgcgtagcttaggctaatcacatagcatcatgtataagtaaacgcgccaaaaagctcctcggtaaataggggctctttcgcgcgtttacttgtttaaacagttttcttgtatacaaaccgtgagtttttttcgtagatgtggtaaagatagtaagtaacgaatgagagattacggaaaggagggacgggttatgaggcacaaacctcaaacacgctccaaggtgctttcggctgacgatggtgtggatatcgttggagatgttcacggctgttacgacgaatttatagaattgctcaaacgctt; SEQ ID NO.13.

[0077] (3) Construction of homologous recombination knockout vector:

[0078] like Figure 1 As shown in A, HAF, Apra R , HAR and vector backbone pE194 fragments were mixed (the final concentration of each component was 30 ng / L), 0.5 μL T4 DNA polymerase and 2 μL buffer (NEBuffer, B7202S) were added; in vitro ligation was performed through the following procedures: 30°C, 20 min, 75°C, 20 min, 50°C, 30 min; the ligation product was then passed through a membrane to remove salt ions, and then the product was transferred into E. coli GB05-dir cells by electroporation, and Apra RThe positive transformants were screened for resistance, and the transformants were identified by BstZ17I and SmaI digestion and sequencing to obtain the knockout vector pE194-liaR / S-ko-HAF-aprA-HAR.

[0079] (4) Construction of genetically recombinant Bacillus brevis engineering bacteria:

[0080] Preparation of competent cells of Bacillus brevis: Take an appropriate amount of wild-type Bacillus brevis X23 glycerol culture from a -80℃ refrigerator, streak it on an LB plate, and culture it at 30℃ for 24h; pick a single colony and inoculate it into 1mL of LB medium, place it on a constant temperature oscillator, 30℃, 900r / min, and culture it overnight; take 40μL of the overnight culture solution, transfer it to 1.3mL of fresh LB liquid medium, 900r / min, and culture it for 4h, OD 600 About 2.0; centrifuge the culture solution at 4°C, 9000r / min for 1 minute, remove the supernatant, and obtain competent cells.

[0081] The homologous recombination knockout vector correctly constructed in step (3) was transferred into wild-type Brevibacillus X23 by referring to the method of Brevibacillus Expression System II (Takara Biotechnology: Brevibacillus Expression System II Takara Biotechnology).

[0082] Schematic diagram of the stable inheritance of the resistance fragment integrated into the chromosome of Bacillus brevis is shown in Figure 1 B. Transformants were cultured in a medium containing Apra R (10 μg / mL) was screened on solid LB and inverted at 30°C for 1 day; the transformants were picked and the bacterial liquid PCR was performed using primers Apra-F2 and Apra-R2, and Apra R The primers of the resistance gene (Apra-F2 and Apra-R2) were used as probes to detect that the homologous recombinant plasmid had been successfully transferred into Bacillus brevis X23. The PCR results were as follows: Figure 2 As shown in A (theoretical band is 774 bp, excluding the resistance gene Apra R promoter sequence).

[0083] The sequences of Apra-F2 and Apra-R2 are as follows:

[0084] Apra-F2: tgcaatacgaatggcgaaaagc; SEQ ID NO.14;

[0085] Apra-R2: tcagccaatcgactggcgagcg; SEQ ID NO. 15.

[0086] The correct transformants were inoculated in LB medium without antibiotics at 37°C and cultured for 14 hours to lose the knockout vector, and then streaked on the LB plate. After a single colony grew, a single colony was picked and streaked on an apramycin (10 μg / mL) plate and an erythromycin (1.5 μg / mL) plate, respectively, to screen the transformants that could only grow on the apramycin resistance plate but not on the erythromycin plate, that is, the transformants that might be the correct knockouts; the screened transformants were subjected to bacterial liquid PCR detection with double primers (TF\Q2 and TR\Q3) in 1 mL of LB medium containing Apra, and the results showed that the bands of theoretical sizes (1473 bp and 1302 bp, respectively) could be detected. The PCR detection results are as follows: Figure 2 B, indicating that the two-component regulatory factor LiaRS in Bacillus brevis X23 was successfully knocked out to obtain the engineered Bacillus brevis ΔliaR / S.

[0087] The primer sequences are as follows:

[0088] TF: gcagcaattctggacgaagt; SEQ ID NO.16;

[0089] TR: caatggcgtaagcagcctgac; SEQ ID NO.17;

[0090] Q2: gttgagaagctgaccgatgag; SEQ ID NO.18;

[0091] Q3: aggaaggtccagtcggtcat; SEQ ID NO.19.

[0092] Test Example 1

[0093] X23-WT and ΔliaR / S strains were activated on solid LB plates, and then a single colony of each strain was cultured in 1.0 mL of liquid LB medium at 30 °C overnight and transferred to 50 mL of fresh liquid NB fermentation medium (peptone 10 g / L, beef extract 3 g / L, NaCl 5 g / L, glucose 10 g / L) to reach an initial density (OD 600 ) was 0.1, and the culture was shaken at 30°C and 180r / min. The fermentation period was 72h, and samples were taken every 12h to measure the sample OD 600 The growth curve was drawn with 3 biological replicates for each sample. The effect of liaR / S deletion on the growth rate of X23 was compared by continuous culture in NB liquid medium. The results of strain growth curve determination showed that the growth trends of the two strains were basically the same ( Figure 3 ), fermented for 18 h after inoculation, OD of ΔliaR / S 600The results showed that the growth trend of the mutant strains did not change due to the knockout of liaR / S, but the knockout of liaR / S was not conducive to the accumulation of bacterial biomass. The results also showed that the improvement of antibacterial activity was not due to the change of biomass.

[0094] Test Example 2

[0095] The cells were collected at 12, 24, 36, 48, 60 and 72 h of culture to extract RNA (Kit: Full-length Gold RNA Kit); mRNA was reverse transcribed into cDNA using the TransScript All-in-One Single-Strand Synthesis Kit. Using edeP as the target gene (edeP is the first gene in the edeine biosynthesis gene cluster) and 16S rRNA as the internal reference gene, RT-qPCR was performed on each sample with 3 biological replicates. The primers used to detect the edeP gene were RT-edeP-F / R; the primers used to detect the 16S rRNA gene were RT-16S-F / R.

[0096] The specific primer sequences are as follows:

[0097] RT-edeP-F:CGCAGGAAGAACAGGAGAGT;SEQ ID NO.20;

[0098] RT-edeP-R:ACCGTCCACAACCAGATGAT;SEQ ID NO.21;

[0099] RT-16S-F: ATGCGTAGAGATGTGGAGGAA; SEQ ID NO.22;

[0100] RT-16S-R: GCGGAGTGCTTATTGCGTTA; SEQ ID NO. 23.

[0101] Reaction system (30 μL) and procedure: 15 μL SYBR Green mixture (Abclonal, 2X UniversalSYBR Green Fast For qPCR Mix), 0.5 μL each of upstream and downstream primers, 1.5 μL cDNA, add water to 30 μL. Retention phase: 50℃2min, 95℃10min; PCR phase: 95℃30s, 55℃30s, 72℃30s, 40 cycles; Melting curve phase: 95℃15s, 60℃1min, 95℃1s; Read the fluorescence value at 95℃1s, perform ROX value correction at the same time, and finally perform fluorescence quantitative PCR product melting curve analysis.

[0102] RT-qPCR results ( Figure 4 ) showed that the expression of edeP in the ΔliaR / S strain reached the highest level at 24h, which was 2.3 times that of X23-WT, but the expression of edeP decreased significantly at 36h. The biosynthesis of edecin started in the early logarithmic growth stage and reached the peak of synthesis at 24h. Knocking out liaR / S helped the mutant strain synthesize more edecin at 24h.

[0103] Test Example 3

[0104] Antibacterial test: The engineered bacteria ΔliaR / S and X23-WT were activated separately and cultured in NB fermentation medium. The initial OD 600 ≈0.1, sampling once every 12 hours, fermentation culture for 72 hours, the bacterial solution obtained by sampling at each period was centrifuged and the supernatant was filtered through a 0.22μm microporous filter membrane and stored at -20℃ for later use. Take 100μL of the fermentation liquid supernatant and add it to the wells of the Ralstonia solanacearum antagonistic plate, use sterile NB liquid culture medium as the blank control (CK), place the plate after spotting in a 30℃ incubator, and measure the diameter of the inhibition zone by the cross method after constant temperature culture for 18 hours. The strength of the antibacterial ability is represented by the size of the inhibition zone radius. The experiment was repeated 3 times. The results show ( Figure 5 ), X23 and ΔliaR / S had no inhibition zone at 0-12h, indicating that at 12h, the two strains had no antibacterial activity. After 24h, the antibacterial activity of ΔliaR / S at each stage was significantly higher than that of the wild type. The results showed that knocking out liaR / S promoted the synthesis of edemacin and enhanced the antibacterial activity of the strain.

[0105] Antagonist plates were prepared as follows:

[0106] a) Activate the target bacteria R. solanacearum GMI1000 on LB plates, pick a single colony and inoculate it into 1 ml LB liquid medium, and culture it at 30°C and 900 rpm for 14 h;

[0107] b) Take overnight bacteria (10 8 cfu / mL) was mixed with LB solid medium melted and cooled to 55°C and poured into a plate (quantitative: 10 μL of bacterial solution was added to every 52.5 mL of LB medium, about 17.5 mL per plate);

[0108] c) After the bacteria-containing plate solidifies, use a sterilized borer (hole diameter 7 mm) to punch holes for later use.

[0109] Test Example 4

[0110] After the strain was activated, NB fermentation medium was used for fermentation culture, and the initial OD 600≈0.1, the culture conditions were 30℃, 180r / min. The fermentation broth sample was taken at 48h of fermentation, the sample was centrifuged at high speed, the supernatant was retained, and a 0.22μm pore size filter was used for sterilization. The sample was detected and analyzed by high performance liquid chromatography-mass spectrometry (HPLC-MS) for edeine A (m / z 755.44[M+H] + ) and edeine B (m / z 797.46[M+H] + ) The change in peak area was used to reflect the change in the total production of ivermectin. Three biological replicates were set for each sample. Chromatographic conditions: A 2.1mm*100mm, 3μm particle size chromatographic column (Shimadzu AQ-C18 HP) was used, the mobile phase was A: 0.1% formic acid-water; B: acetonitrile; the gradient was: 0-3min 2% B, 3-5min 30% B, 5-11min 100% B, 11-13min 2% B, 13-16min 2% B; the flow rate was 0.3mL / min; the column temperature was 40℃, the detection wavelength was 278nm, and the sample load was 1μL. Mass spectrometry conditions: MRM scanning mode, positive ion, molecular weight scanning range 100m / z-1000m / z, nebulizer flow rate 3L / min, heating gas flow rate 10L / min, interface temperature 200℃, DL temperature 200℃, heating block temperature 350℃, dryer flow rate 10L / min. Comparison of edeine A (m / z755.44[M+H] + ) and edeine B (m / z 797.46[M+H] + ) peak area changes. HPLC-MS analysis was performed using a quadrupole time-of-flight mass spectrometer (UPLC-QTOF; Agilent 6545) equipped with qualitative analysis software. The processing results are shown in Figure 6 Compared with X23-WT, the brevis engineered bacteria ΔliaR / S obtained by the present invention has an increase in the yield (peak area) of edemacin by about 1.3 times. Therefore, the brevis engineered bacteria of the present invention can achieve efficient production of edemacin by fermentation.

[0111] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A genetically engineered bacterium, characterized in that: Brevibacillus brevis X23 was used as the original strain, and the two-component regulator LiaRS was knocked out; The gene numbers of the two-component regulator LiaRS are A616_RS05710 and A616_RS05715, and the nucleotide sequences are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively.

2. The method for constructing a genetically engineered bacterium according to claim 1, characterized in that: The specific steps are as follows: (1) Using the upstream and downstream homology arms of LiaRS, resistance genes and vector backbone, a homologous recombination knockout vector was constructed; The nucleotide sequence of the resistance gene is shown in SEQ ID NO.3; The upstream homology arm nucleotide sequence of the LiaRS is shown in SEQ ID NO.12; the downstream homology arm nucleotide sequence is shown in SEQ ID NO.13; The vector backbone is obtained by amplification using pE194 plasmid as template and primers pE194-F / pE194-R; (2) The LiaRS in the genome of Bacillus brevis X23 was knocked out by homologous recombination technology to obtain a genetically engineered bacterium.

3. The method for constructing a genetically engineered bacterium according to claim 2, characterized in that: The sequences of primers pE194-F / pE194-R are as follows: pE194-F: cagctgcctcgcgcgtttcggtga; SEQ ID NO.6; pE194-R: gttaagggatgcataaactgcatc; SEQ ID NO.

7.

4. Use of the genetically engineered bacteria according to claim 1 in high production of edemacin.

5. Use of the genetically engineered bacteria according to claim 1 in inhibiting Ralstonia solanacearum.

6. Use of the genetically engineered bacteria constructed by the method according to claim 2 or 3 in high production of edemectin.

7. Use of the genetically engineered bacteria constructed by the method according to claim 2 or 3 in inhibiting Ralstonia solanacearum.

Citation Information

Patent Citations

  • Sensors for detection and quantification of microbiological protein secretion

    CN107532140A